References

1000 genomes project consortium. A global reference for human genetic variation

10.1038/nature15393 · 2015 · External reference

Meta-analysis of prevalence

10.1136/jech-2013-203104 · 2013 · External reference

Controlling the false discovery rate: a practical and powerful approach to multiple testing

10.1111/j.2517-6161.1995.tb02031.x · 1995 · External reference

Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing

10.1002/cpt.113 · 2015 · External reference

Clinical pharmacogenetics consortium guideline for CYP2D6, CYP2C19 and CYP2B6 genotypes and serotonin reuptake inhibitor antidepressants

10.1002/cpt.2903 · 2023 · External reference

Incorporation of pharmacogenomics into routine clinical practice: the clinical pharmacogenetics implementation consortium guideline development process

10.2174/1389200215666140130124910 · 2014 · External reference

Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and Dutch pharmacogenetics working group

10.1111/cts.12692 · 2020 · External reference

Unresolved reference

2019 · External reference

Unresolved reference

2024 · External reference

The clinical pharmacogenetics implementation consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms

10.1002/cpt.2557 · 2022 · External reference

Clinical pharmacogenetics implementation consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy

10.1002/cpt.2149 · 2021 · External reference

Meta-analysis in clinical trials

10.1016/0197-2456(86)90046-2 · 1986 · External reference

Clinical pharmacogenetics implementation consortium guideline for CYP2B6 and efavirenz-containing antiretroviral therapy

10.1002/cpt.1477 · 2019 · External reference

Pharmacogenomic information in drug labels: European medicines agency perspective

10.1038/tpj.2014.86 · 2015 · External reference

Pharmacogenomics - drug disposition, drug targets, and side effects

10.1056/nejmra020526 · 2003 · External reference

Complexities of CYP2D6 gene analysis and interpretation

10.3109/09540261.2013.825581 · 2013 · External reference

Prediction of CYP2D6 phenotype from genotype across world populations

10.1038/gim.2016.80 · 2017 · External reference

The pharmacogene variation (PharmVar) consortium: incorporation of the human cytochrome P450 allele nomenclature database

10.1002/cpt.910 · 2018 · External reference

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin

10.1038/clpt.2008.10 · 2008 · External reference

The GenomeAsia 100K project enables genetic discoveries across Asia

10.1038/s41586-019-1793-z · 2019 · External reference

Clinical pharmacogenetics implementation consortium guideline for HLA-B genotype and allopurinol dosing

10.1038/clpt.2012.209 · 2013 · External reference

Quantifying heterogeneity in a meta-analysis

10.1002/sim.1186 · 2002 · External reference

Standardized biogeographic grouping system for annotating populations in pharmacogenetic research

10.1002/cpt.1322 · 2019 · External reference

Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan

10.1038/s41431-022-01243-2 · 2023 · External reference

Integrating rare genetic variants into pharmacogenetic drug response predictions

10.1186/s40246-018-0157-3 · 2018 · External reference

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict irinotecan toxicity

10.1200/jco.2004.07.173 · 2004 · External reference

Clinical pharmacogenetics implementation consortium guideline for pharmacogenetics-guided warfarin dosing: 2017 update

10.1002/cpt.668 · 2017 · External reference

The mutational constraint spectrum quantified from variation in 141,456 humans

10.1038/s41586-020-2308-7 · 2020 · External reference

Clinical pharmacogenetics implementation consortium guideline for CYP2C9 and HLA-B genotypes and phenytoin dosing: 2020 update

10.1002/cpt.2008 · 2021 · External reference

Pharmacogenomic biomarkers in US FDA-approved drug labels (2000-2020)

10.3390/jpm11030179 · 2021 · External reference

Estimation of the warfarin dose with clinical and pharmacogenetic data

10.1056/nejmoa0809329 · 2009 · External reference

ClinVar: improving access to variant interpretations and supporting evidence

10.1093/nar/gkx1153 · 2018 · External reference

Emerging strategies to bridge the gap between pharmacogenomic research and its clinical implementation

10.1038/s41525-020-0119-1 · 2020 · External reference

Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update

10.1002/cpt.2526 · 2022 · External reference

Clinical pharmacogenetics implementation consortium guideline for CYP2C19 and proton pump inhibitor dosing

10.1002/cpt.2015 · 2021 · External reference

Single nucleotide and structural variants of CYP2D6 gene in kinh Vietnamese population

10.1097/md.0000000000015891 · 2019 · External reference

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

10.1136/bmj.n71 · 2021 · External reference

Unresolved reference

2025 · External reference

Pharmacogenomics: current status and future perspectives

10.1038/s41576-022-00572-8 · 2023 · External reference

Genomics is failing on diversity

10.1038/538161a · 2016 · External reference

The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update

10.1038/clpt.2014.125 · 2014 · External reference

Pharmacogenomics in the clinic

10.1038/nature15817 · 2015 · External reference

Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update

10.1002/cpt.1304 · 2019 · External reference

The clinical pharmacogenetics implementation consortium: 10 years later

10.1002/cpt.1651 · 2020 · External reference

Pharmacogenomics

10.1016/s0140-6736(19)31276-0 · 2019 · External reference

Prevalence of pharmacogenomic variants in 100 pharmacogenes among Southeast Asian populations under the collaboration of the Southeast Asian pharmacogenomics research network (SEAPharm)

10.1038/s41439-021-00135-z · 2021 · External reference

Clinical pharmacogenetics implementation consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update

10.1002/cpt.161 · 2016 · External reference

Comparison between the HLA-B*58:01 allele and single-nucleotide polymorphisms in chromosome 6 for prediction of allopurinol-induced severe cutaneous adverse reactions

10.1155/2017/2738784 · 2017 · External reference

Seriously misleading results using inverse of freeman-tukey double arcsine transformation in meta-analysis of single proportions

10.1002/jrsm.1348 · 2019 · External reference

Preferred reporting items for systematic review and Meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation

10.1136/bmj.g7647 · 2015 · External reference

The missing diversity in human genetic studies

10.1016/j.cell.2019.02.048 · 2019 · External reference

Pharmacogenetics: from bench to byte - an update of guidelines

10.1038/clpt.2011.34 · 2011 · External reference

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

10.1016/s0140-6736(22)01841-4 · 2023 · External reference

Clinical pharmacogenetics implementation consortium guideline for CYP2C9 and nonsteroidal anti-inflammatory drugs

10.1002/cpt.1830 · 2020 · External reference

Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam

10.1007/s00228-008-0573-8 · 2009 · External reference

CYP2C19 genetic polymorphism in the Vietnamese population

10.1080/03014460.2019.1685546 · 2019 · External reference

An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine

10.1002/cpt.2350 · 2021 · External reference